New tool reveals hidden metabolic weakness in blood cancers: Duke-NUS study
Peer-Reviewed Publication
Updates every hour. Last Updated: 9-Dec-2025 21:11 ET (10-Dec-2025 02:11 GMT/UTC)
Scientists have developed a new computational tool that maps multi-gene pathways more comprehensively than ever before.
The study uncovered a previously unknown protein pathway that, when blocked, kills blood cancer cells.
The discovery could lead to new therapies for patients with drug-resistant blood cancers.In a special 11 December event for science journalists, the Science Press Package team will revisit the topic recognized as Science’s Breakthrough of the year in 2023: the development of GLP-1 receptor agonists to treat obesity and their efficacy in blunting obesity-associated health problems. The Mani L. Bhaumik Breakthrough of the Year Award that the American Association for the Advancement of Science, publisher of Science, gave to researchers whose work best underpinned the GLP-1 breakthrough was steered by a committee that included Dr. Katherine Saunders, obesity physician at Weill Cornell Medicine and co-founder of FlyteHealth. Dr. Saunders routinely works with media, responding to questions about how GLP-1s are prescribed as part of comprehensive cardiometabolic care. She recognizes opportunities for news stories on such topics to more accurately reflect the realities of the biology of obesity as a disease, and the science taken into account when treating patients with GLP-1s.
In this briefing, Dr. Saunders will take your questions on these topics. She will be joined by Dr. Robyn Pashby, a clinical health psychologist specializing in obesity-related behavioral science, and Dr. Tracy Zvenyach, a health policy researcher and Director of Policy Strategy at the Obesity Action Coalition. Dr. Pashby will discuss topics including the neurobehavioral links between mental health and obesity, and how GLP-1 medications influence motivation, reward processing, and treatment engagement. Dr. Tracy Zvenyach, who engages in policy advocacy and research to improve access to obesity treatments, will outline the coverage landscape, including how standard health insurance is working, and how it isn’t. She will also discuss policy implications of continued research into GLP-1s, which show a growing range of benefits.
The event will be held at 10am US ET on Thursday 11 December on Zoom. Register now to attend: https://aaas.zoom.us/webinar/register/WN_HwsyjhaBRR2RurCbJ5vhXw. Please plan to bring your questions! Note: This event is not tied to embargoed content.
Road crossings need to slow down to allow people with mobility issues and older pedestrians enough time to use them, research has indicated.
The time interval of crossings in the UK is more than two seconds shorter than people with reduced mobility need, according to a new study by researchers at the Universities of Bath, Birmingham and Exeter.
Interactions among viruses can help them succeed inside their hosts or impart vulnerabilities that make them easier to treat. Scientists are learning the ways viruses mingle inside the cells they infect, as well as the consequences of their socializing. Although it is debatable whether viruses are living things, they do compete, cooperate and share genome materials that can sometimes alter their responses to antiviral drugs, result in new variants or play a role in virus evolution. A paper today in Nature Ecology & Evolution by UW Medicine scientists looks at the evolution of poliovirus resistance to a promising experimental antiviral drug, pocapavir. While it seemed counterintuitive, the researchers demonstrated that lowering the potency of pocapavir could improve the situation by enhancing the survival of enough susceptible viruses to continue sensitizing the resistant ones.
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company’s CRISPR-based Cellgorithm™ technology, which lays the groundwork for programmable control of gene activity in human stem cells and offers an alternative to the slow, variable manual processes researchers use today.
In traditional cell differentiation, scientists expose stem cells to a series of growth factors, media changes, and environmental cues over months to coax them into a desired lineage. Each step is highly sensitive to timing and reagent conditions, leading to inconsistent results that are difficult to reproduce or scale. Syntax Bio aims to address this challenge.
“Our research shows that we can now achieve an unprecedented level of temporal control over how genes turn on inside stem cells,” said Ryan Clarke, PhD, Syntax Bio co-founder, chief technology officer, and study co-author. “It’s the foundation of a new programming language for cells, one that we believe can eventually surpass the slow, inconsistent cell differentiation approaches researchers have relied on for years. Our goal is to make cell programming as reliable and scalable as running software.”
A new monthly series in The Lancet is going beyond clinical diagnoses, tapping experts from the social sciences and humanities, as well as community members from around the world. The resulting cases provide a critical lens into the cultural and social forces that contribute to each patient’s condition — not just the biological factors. Each unpacks a framework or concept in the social sciences and humanities that researchers hope readers will incorporate into their own practice, leadership or policy-making.